RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Add like
Add dislike
Add to saved papers

Retinal stroke. Is the patient at risk?

A follow-up study was performed to determine the general prognosis for health and life in 86 patients with retinal artery occlusion or ophthalmoscopically observed retinal cholesterol emboli, not subjected to surgery. Survivorship rates and incidence of subsequent cerebrovascular disease were calculated and compared to expected survivorship rate of an age-and sex-matched population. Results were as follows: the patient group with retinal stroke as a whole showed a statistically significant diminished survivorship rate from the third year onward; patients with retinal occlusions without visible emboli had a survivorship rate comparable to the matched control; but patients with visible emboli demonstrated a strikingly diminished survivorship rate. In the study group, the combined time corrected annual stroke mortality was 1,695 per 100,000 (four to five times greater than expected), but the largest single cause of death was cardiovascular disease.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app